Systemic Ozone Therapy by Rectal Insufflation for Immunoglobulin A Deficiency

Area of Science:

• Immunology
• Medical Ozone Therapy
• Clinical Trials

Background:

• Selective IgA deficiency is a primary immunodeficiency characterized by impaired antibody production.
• Current management focuses on infection prevention and treatment, lacking specific replacement therapies.
• Ozone therapy's known immunomodulatory and antioxidant properties warrant investigation for IgA deficiency.

Purpose of the Study:

• To evaluate the efficacy and safety of ozone therapy in patients with IgA deficiency.
• To assess changes in immunoglobulin levels and oxidative stress biomarkers.
• To compare ozone therapy outcomes against leukocyte transfer factor treatment.

Main Methods:

• A randomized controlled phase 2 clinical trial involving 40 patients (ages 5-50) with IgA deficiency.
• Experimental group received ozone therapy via rectal insufflation (2 cycles, 40 doses total).
• Control group received subcutaneous leukocyte transfer factor (Hebertrans) for 12 weeks.

Main Results:

• Ozone therapy significantly increased IgG and IgM levels in 70% of patients.
• Reduced pro-oxidation biomarkers and oxidative stress, with glutathione modulation and increased antioxidant enzymes observed.
• 85% of patients in the ozone group achieved complete therapeutic response versus 45% in the control group.

Conclusions:

• Ozone therapy via rectal insufflation is a feasible, safe, and minimally invasive option for IgA deficiency.
• The treatment demonstrates significant antioxidant and immunomodulatory effects.
• Ozone therapy offers substantial clinical benefits for patients with this immunodeficiency.